Patents Assigned to CHU DE TOULOUSE
  • Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
    Patent number: 9125862
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Rechereche Medicale (INSERM), Universite de la Mediterranee, CHU de Toulouse
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux
  • Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient
    Publication number: 20150005229
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 1, 2015
    Applicants: Institut National de la Sante et de la Rechereche Medicale (INSERM), Universite de la Mediterranee, CHU de Toulouse
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux
  • Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
    Patent number: 8853158
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: October 7, 2014
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Chu de Toulouse, Universite d'Aix-Marseille
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux
  • METHOD FOR PREDICTING INSULINOPENIC TYPE 2 DIABETES
    Publication number: 20140186829
    Abstract: The present invention relates to an in vitro method, for predicting a risk of onset of type 2 diabetes in a subject, which method comprises the steps of: a) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) comparing said measured concentration of bacterial 16S rDNA to a threshold level; wherein a measured concentration of bacterial 16S rDNA higher than the threshold level is indicative of an increased risk of onset of type 2 diabetes in the subject, and a measured concentration of bacterial 16S rDNA lower than the threshold level is indicative of a decreased risk of onset of type 2 diabetes in the subject.
    Type: Application
    Filed: April 2, 2012
    Publication date: July 3, 2014
    Applicants: CHU De Toulouse, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Remy Burcelin, Jacques Amar, Beverly Balkau
  • USE OF BLOOD OR TISSUE BACTERIOME FOR PREDICTION, DIAGNOSIS AND PREVENTION OF METABOLIC DISEASES AND THEIR CARDIOVASCULAR COMPLICATIONS
    Publication number: 20140086954
    Abstract: The present invention relates to the use of the bacterial flora for vaccine development, identification of therapeutic targets and prediction and/or diagnosis of metabolic diseases, such as diabetes, overweight and obesity, and their cardiovascular complications. In particular, the present invention provides immunogenic or vaccinal composition for preventing metabolic diseases and cardiovascular complications using attenuated or inactivated bacterial flora, or antigens derived thereof. The present invention also provides methods for identifying prognostic markers for metabolic diseases onset and cardiovascular complications and methods for in vitro prognosis of metabolic diseases and cardiovascular complications using bacterial flora.
    Type: Application
    Filed: April 2, 2012
    Publication date: March 27, 2014
    Applicants: CHU de Toulouse, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rémy Burcelin, Jacques Amar, Beverley Balkau
  • METHOD FOR PREDICTING ABDOMINAL OBESITY
    Publication number: 20140088203
    Abstract: The present invention relates to a method, in particular an in vitro method, for predicting a risk of onset of abdominal obesity in a subject, which method comprises the steps of: a1) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) based on the result of the measurement in step a1), determining a risk of onset of abdominal obesity in the subject.
    Type: Application
    Filed: April 2, 2012
    Publication date: March 27, 2014
    Applicants: CHU de Toulouse, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Jacques Amar, Rémy Burcelin
  • Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient
    Publication number: 20130102528
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Application
    Filed: May 25, 2011
    Publication date: April 25, 2013
    Applicants: CHU DE TOULOUSE, UNIVERSITE DE LA MEDITERRANEE
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux